The search for treatments for inclusion body myositis
- PMID: 37739563
- DOI: 10.1016/S1474-4422(23)00327-7
The search for treatments for inclusion body myositis
Conflict of interest statement
MdV has consulted for Novartis, Dynacure, and Argenx. JDB has participated on data safety monitoring boards or advisory boards for Argenx, Biogen, Sanofi, Alexion, UCB Pharma, Amylyx, and Amicus Pharma.
Comment on
-
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. Lancet Neurol. 2023. PMID: 37739573 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources